Jennifer Densmore
Primary Care · Carrollton, GANPI 1841754611
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,496 of the $6,216 with a category attached, or 72.3%. 32 manufacturers reported payments, led by Medtronic at 41.0% of the total. 2025 is the largest year on record at $2,338, more than ten times the $47 reported in 2021. Among primary care clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 227 payments — averaging $27.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Novo Nordisk$895
- Lilly USA, LLC$486
- AbbVie$230
- Mannkind Corporation$185
- Boehringer Ingelheim$184
- plus $2K from 26 others
What the payments were for
- Travel & lodging$1,67827%
- Food & beverage$4,49672%
- Education$431%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 36 | $2,548 |
| Novo Nordisk | 61 | $895 |
| Lilly USA, LLC | 27 | $486 |
| AbbVie | 13 | $230 |
| Mannkind Corporation | 8 | $185 |
| Boehringer Ingelheim | 10 | $184 |
| Tandem Diabetes Care, Inc. | 8 | $177 |
| Novartis | 8 | $165 |
| Averitas Pharma Inc. | 2 | $146 |
| Amgen(2 entities) | 7 | $129 |
| Shockwave Medical, Inc | 1 | $108 |
| Dexcom, Inc. | 4 | $101 |
| Corcept Therapeutics | 4 | $90 |
| Xeris Pharmaceuticals, Inc. | 4 | $89 |
| Abbott | 4 | $86 |
| BETA Bionics, Inc. | 3 | $67 |
| Merck | 3 | $56 |
| Sanofi-aventis U.S. LLC | 2 | $53 |
| Insulet Corporation | 3 | $52 |
| Amneal Pharmaceuticals LLC | 2 | $48 |
| Pfizer | 2 | $47 |
| Amarin Pharma, Inc. | 2 | $41 |
| Bayer | 2 | $38 |
| Astellas Pharma US Inc | 2 | $38 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $37 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Seqirus USA Inc | 1 | $18 |
| IBSA Pharma Inc. | 1 | $18 |
| Acella Pharmaceuticals, LLC | 1 | $17 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
| Boston Scientific | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,216 in reported general payments places this provider in the 90th percentile of 235 primary care providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 89 | $124,885 |
| JardianceEmpagliflozin | 46 | $65,731 |
| MounjaroTirzepatide | 27 | $37,271 |
| TrulicityDulaglutide | 19 | $35,107 |
| RybelsusSemaglutide | 14 | $24,272 |
| LinzessLinaclotide | 18 | $16,262 |
| EliquisApixaban | 18 | $15,975 |
| TradjentaLinagliptin | 15 | $15,384 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 35 | $10,219 |
| Novolog FlexpenInsulin Aspart | 14 | $6,120 |
| Pentazocine-Naloxone HclPentazocine Hcl/Naloxone Hcl | 11 | $2,147 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 22 | $1,652 |
| Ultra-Fine Short Pen NeedlePen Needle, Diabetic | 19 | $1,592 |
| Levothyroxine Sodium | 107 | $1,088 |
| Potassium Chloride | 26 | $1,036 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $895 | $149,157103 claims |
| Boehringer IngelheimJardiance, Tradjenta | $184 | $81,11661 claims |
| Lilly USA, LLCMounjaro, Trulicity | $486 | $72,37946 claims |
| AbbVieLinzess | $230 | $16,26218 claims |
| PfizerEliquis | $47 | $15,97518 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $48 | $1,088107 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 235 primary care providers in Georgia.
Other primary care in Carrollton
- Alyssa FreyCarrollton$4K
- Pamela TurkDouglas$15K
- Morgan JonesLawrenceville$14K
- Jessi HaleColumbus$13K
- Meredith CarrAugusta$12K
- Ashtyn ZaryckiSavannah$12K
- Zanetta BryantNewnan$11K
- Hannah CummingsSuwanee$9K
- Michelle LadewigGainesville$7K
- Lucia OcanoviciuCanton$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.